Cytokinetics, Incorporated
$65.05
▼
-1.14%
2026-04-22 10:12:13
www.cytokinetics.com
NMS: CYTK
Explore Cytokinetics, Incorporated stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$8.11 B
Current Price
$65.05
52W High / Low
$70.98 / $29.31
Stock P/E
—
Book Value
$-5.37
Dividend Yield
—
ROCE
-50.1%
ROE
197.47%
Face Value
—
EPS
$-6.54
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
673
Beta
0.48
Debt / Equity
-1.95
Current Ratio
4.53
Quick Ratio
4.53
Forward P/E
-13.17
Price / Sales
90.95
Enterprise Value
$8.56 B
EV / EBITDA
-14.22
EV / Revenue
97.27
Rating
Buy
Target Price
$92.82
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Greenwich LifeSciences, Inc. | $24.52 | — | $384.32 M | — | -631.87% | -5.43% | $34.1 / $7.78 | $0.16 |
| 2. | Day One Biopharmaceuticals, Inc. | $21.48 | — | $2.22 B | — | -28.56% | -22.74% | $21.49 / $5.63 | $4.28 |
| 3. | Celldex Therapeutics, Inc. | $34.38 | — | $2.7 B | — | -54.02% | -40.62% | $35.29 / $17.45 | $7.92 |
| 4. | ProKidney Corp. | $2.1 | — | $634.02 M | — | -54.13% | -43.17% | $7.13 / $0.54 | $-7.13 |
| 5. | X4 Pharmaceuticals, Inc. | $4.19 | — | $372.04 M | — | -32.82% | -75.99% | $6.63 / $1.35 | $2.05 |
| 6. | Alpha Tau Medical Ltd. | $8.11 | — | $706.72 M | — | -44.45% | -61% | $8.6 / $2.5 | $0.88 |
| 7. | Crinetics Pharmaceuticals, Inc. | $40.25 | — | $4.21 B | — | -49.63% | -40.17% | $57.99 / $25.83 | $10.38 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 17.75 M | 1.94 M | 66.77 M | 1.58 M | 16.93 M |
| Operating Profit | -178.37 M | -166.75 M | -111.51 M | -155.63 M | -139.04 M |
| Net Profit | -183.03 M | -306.18 M | -134.37 M | -161.38 M | -150.02 M |
| EPS in Rs | -1.49 | -2.49 | -1.09 | -1.31 | -1.22 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 88.04 M | 18.47 M | 7.53 M | 94.59 M |
| Operating Profit | -612.26 M | -536.25 M | -496.2 M | -324.2 M |
| Net Profit | -784.96 M | -589.53 M | -526.24 M | -388.95 M |
| EPS in Rs | -6.37 | -4.79 | -4.27 | -3.16 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.42 B | 1.4 B | 824.32 M | 1.01 B |
| Total Liabilities | 2.08 B | 1.54 B | 1.21 B | 1.12 B |
| Equity | -659.62 M | -135.37 M | -386.32 M | -107.9 M |
| Current Assets | 916.98 M | 1.11 B | 628.05 M | 795.19 M |
| Current Liabilities | 202.45 M | 179.67 M | 102.68 M | 84.62 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -510.01 M | -395.89 M | -414.33 M | -299.52 M |
| Investing CF | 16.67 M | -553.1 M | 239.25 M | -262.13 M |
| Financing CF | 524.46 M | 930.61 M | 221.32 M | 516.17 M |
| Free CF | -534.82 M | -399.8 M | -415.75 M | -310.85 M |
| Capex | -24.81 M | -3.91 M | -1.42 M | -11.34 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 145.34% | -92.04% | — | — |
| Earnings Growth % | -12.03% | -35.3% | — | — |
| Profit Margin % | -3191.11% | -6988.63% | -411.21% | — |
| Operating Margin % | -2902.72% | -6589.71% | -342.75% | — |
| Gross Margin % | -1737.22% | -4284.1% | -154.59% | — |
| EBITDA Margin % | -2671.23% | -6064.86% | -350.98% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.